570 related articles for article (PubMed ID: 10634134)
1. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
2. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
3. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
5. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
6. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
7. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
11. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
12. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
13. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
[TBL] [Abstract][Full Text] [Related]
14. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A; Dorado P; Ramírez R; González I; Alvarez M; Peñas-Lledó EM; Pérez B; Calzadilla LR
Pharmacogenomics J; 2012 Apr; 12(2):176-83. PubMed ID: 21135868
[TBL] [Abstract][Full Text] [Related]
18. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
